Maintenance Therapy with Aromatase Inhibitor in epithelial Ovarian Cancer (MATAO): Study protocol of a randomized double-blinded placebo-controlled multi-center phase III Trial

A high percentage of epithelial ovarian cancers (EOC) express the estrogen receptor (ER), which is an ideal target for endocrine therapy. Letrozole is a proven, potent aromatase inhibitor, extensively tested and used in the treatment of ER positive breast cancer.